Transforming Alzheimer's Screening
Recipient of the 2019 ADDF's
Diagnostics Accelerator award
RetiSpec is an artificial intelligence (AI) medical imaging company developing tools for the early detection of disease biomarkers in the eye.
Our goal is to enable widespread early detection of Alzheimer’s disease with accessible and scalable screening.
RetiSpec Technology
In a quick eye exam, RetiSpec opens a window of opportunity for timely and specific therapeutic interventions, so the progression of the disease may be slowed or even prevented.
By harnessing hyperspectral imagery and AI, RetiSpec's patented technology allows for the rapid, simple, non-invasive, and cost-effective identification of Alzheimer's biomarkers.
RetiSpec is using computer vision and AI to detect unique signatures of Alzheimer’s biomarkers in a manner of seconds.
Team
ELIAV SHAKED, M.SC
CEO & Co-founder
ROY KIRSHON, MBA
COO & Co-founder
CATHERINE BORNBAUM, PHD, MBA
Head of Clinical Operations & Partnerships
ADAM GRIBBLE, PHD
Lead Scientist
ADAM GRIBBLE, PHD
Lead Scientist
JARED WESTREICH, M.SC
Data Scientist
ALON HAZAN, M.SC
Head of AI
MAÏLIS BIETENHADER, PHD
Ocular Imaging Specialist
In The News
RetiSpec Announces Partnership With Gentex To Commercialize Alzheimer's Disease Detection Technology
"The Gentex-RetiSpec partnership reinforces our commitment to bring to market RetiSpec's novel retinal imaging technology, a widely scalable and affordable way to accurately detect Alzheimer's Disease at both the symptomatic and pre-symptomatic stages," said Eliav Shaked, CEO of RetiSpec.
University of Minnesota collaborates with medical imaging startup RetiSpec
The University’s collaboration with RetiSpec comes following a successful pilot clinical study demonstrating the capabilities of the technology, involving 31 participants both with and without Alzheimer’s.
RetiSpec Receives Award from Alzheimer's Drug Discovery Foundation (ADDF)
Howard Fillit, M.D., Founding Executive Director and Chief Science Officer of ADDF, said, "We believe that RetiSpec's retinal scanner stands out and shows promise as a unique diagnostic tool among a range of technologies in development. The technology has the potential to facilitate early diagnosis, improve the lives of patients and their loved ones and save the healthcare system money and resources. The technology will also be useful in making clinical trials for Alzheimer's disease more efficient."
CABHI is working with RetiSpec to accelerate its technology in Ontario and Canada
The CABHI-funded RetiSpec trial will determine the safety and effectiveness of the technology through human clinical testing, and help spur commercialization of the technology in Ontario and Canada – to get it into the hands of those who need it most.
An Eye Scan For Alzheimer's? Toronto Memory Program is Looking Into It (CTV NEWS)
An Eye Scan For Alzheimer's? Toronto Memory Program Is Looking Into It.
Dr. Sharon Cohen discuss the RetiSpec technology and the study conducted at Toronto Memory Program.
From the Lab to Life: A Retinal Scanner for Early Detection of Alzheimer’s Disease
Ontario Brain Institute backed RetiSpec to accelerate growth in Ontario, Canada. RetiSpec has developed software and “plug and play” hardware components that can be applied directly to existing retinal cameras readily found in optometrists’ offices.
Partners
Contact Us
Toronto, ON, Canada
© 2021 RetiSpec Inc. All rights reserved.
RetiSpec's technology is currently for research use only